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The role of the phospholipase inhibitor proteins, lipocortin-I and -11, in tumor necrosis factor (TNF)-mediated cytotoxicity against L929 fibrosarco- 
ma cells was investigated. We previously reported that TNF-mediated cytotoxicity was inhibited by dexamethasone (DEX), suggesting an involve- 
ment of lipocortins [l]. Now we show that, despite inhibition by DEX of TNF-induced arachidonic acid release, DEX has no effect on the synthesis 
of these lipocortins. Moreover, TNF itself has no effect on the synthesis and phosphorylation of lipocortin-I and -11. Also there was no difference 
in expression levels of lipocortin-I and -11 between TNF-sensitive and -resistant cells. These data strongly suggest hat the protective ffect of DEX 
and other glucocorticoids is not mediated by lipocortins. 
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1. INTRODUCTION 
TNF is a protein that exerts cytotoxic and cytostatic 
effects against certain tumor cell lines, both in vitro and 
in vivo, while sparing normal cells [2]. New information 
is beginning to shed light on the molecular mechanisms 
involved in TNF-mediated destruction of transformed 
cells in vitro. 
Our in vitro studies with murine L929 cells indicate 
that one of the intracellular steps occurring after TNF 
treatment is activation of a PLA2 [1,3]. Inhibitors of 
PLA2 activation, such as DEX, quinacrine and high 
concentrations of indomethacin, blocked TNF- 
mediated cell destruction. In addition, we and others 
found an increased release of AA from phospholipids 
into the cell supernatant upon TNF-treatment ([3] and 
our unpublished results). 
The mechanism of DEX action is thought to involve 
synthesis of lipocortins, which are phospholipase in- 
hibitors [4]. Several authors postulated an involvement 
of lipocortins in TNF action [ 1,5,6]. Hence we were in- 
terested to determine whether DEX could inhibit the 
TNF-induced AA release and whether lipocortins 
played any role in the observed effects. We also 
wondered whether TNF could activate PLA2 by 
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decreasing lipocortin synthesis or increasing lipocortin 
phosphorylation, the latter leading to its inactivation 
171. 
2.. MATERIALS AND METHODS 
2.1. Source and cultivation of cells 
L929, HeLaD981AH2, MCF7 and FS4 cells were obtained and 
cultured as described previously (81. 
2.2. Source of antibodies, lipocortin-II and TNF 
Anti-lipocortin-I was a gift from Dr B. Pepinsky (Biogen, Cam- 
bridge, MD, USA). Anti-murine lipocortin-II and purified lipocortin- 
II protein were kindly provided by Dr V. Gerke (Max-Planck-Institut, 
Gattingen, FRG). Anti-human lipocortin-II was a gift from Dr C.M. 
Isacke (Salk Institute, San Diego, CA, USA). Human TNP was 
prepared as described [9]. The preparation had a specific activity of 
2-3 x 10’ U/mg protein and contained less than 13 ng endotoxin/mg 
protein. 
2.3. TNF-mediated cytotoxicity and AA .release 
Measurement of TNF-mediated cytotoxicity and TNF-induced AA 
release were performed as described previously [8]. 
2.4. In vitro phosphorylation 
In vitro phosphorylation reactions were carried out as described by 
Pepinsky and Sinclair [ 101. Cells were pretreated with 100 U TNF/ml 
or 200 ng EGF/ml (Boehringer Mannheim, Mannheim, FRG) before 
preparation of the membranes. The phosphorylation reaction was 
carried out in the absence or presence of 1000 U TNF/ml or 2 pg 
EGF/ml. The reactions were stopped by adding a 300-fold excess of 
cold ATP in lysis buffer and freezing at - 20°C. 
2.5. Metabolic labeling experiments 
Cells in a 6-well plate were pretreated for different time periods 
with 1000 U TNF/ml. labeled with 100&i [“Slmethionine or 1 mCi 
“Pi/well and lysed as described previously [lo]. 
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2.6. Immunoprecipitation 
The appropriate antisera were added to equal amounts (10’ cpm) of 
labeled lysate and the samples were incubated for 2 h at 4°C. The im- 
mune complexes were collected by adsorption to protein A-Sepharose 
for 1 h at 4°C with continuous mixing. The adsorbed immune 
precipitates were washed 4 times with 1 ml buffer (10 mM NazHPOd, 
pH 7.2; 155 mM NaCl; 1% NP-40; 0.1% SDS; 1% sodium deox- 
ycholate; 30 mM NaNr; 1 mM NaF; 1 mM EDTA), suspended in 50 
yl of 1.5 x Laemmli sample buffer [ll], heated at 60°C for 10 min 
and subjected to electrophoresis in SDS-containing, 10% 
poIyac~l~ide gels. The gels were fixed with 50% trichloroacetic 
acid and fluoro~aph~ with a Fuji Rx Medical film (Tokyo, Japan). 
Molecular weight protein standards were from Amersham Interna- 
tional (Amersham, England). 
3. RESULTS 
3 I) 1. LlEX ~~~~~jts TNF-induced AA release 
L929 cells, prelabeled with t3H]AA, were treated 
with 50 /rM DEX for 1 h before control medium or 
TNF-containing medium was added. 5 h later, the 
amount of radioactivity in the supernatant was deter- 
mined. The effect of DEX on TNF-mediated cytotoxici- 
ty was measured in a-36-h assay as described in section 
2. Both TNF-induced AA release and TNF-mediated 
cytotoxicity were inhibited by DEX (table 1). 
3.2. DEX does not induce the synthesis or secretion 
of lipocortin-I or -II in L929 cells 
DEX ~bits TNF-mediated cytotoxicity in a 
transcription-independent mamer [ 11. The possible role 
of lipocortins in mediating this response was in- 
vestigated by studying the effect of DEX on in- 
tracellular and extracellular lipocortin-I and -11 levels. 
L929 cells were labeled for 5 h with [35S]methionine and 
50pM DEX was added at different times (3 h, 6 h, 8 h 
and 24 h) before the end of the labeling. Intracellular 
and extracellular lipocortin levels were then determined 
by immunoprecipitation and gel electrophoresis. The 
cell-associated amounts of lipocortin-I (fig.1) and -11 
(data not shown) appeared to be unchanged after DEX 
treatment, while these proteins could not be detected in 
the culture medium. 
3.3. Role of lipocortin expression i the TNF-response 
L929 cells were labeled for 4 h with [35S]methionine 
Table 1 
Effect of DEX on TNF-mediated cytotoxicity and TNF-induced AA 
release from L929 cells 
% survivala fter % [“H&4 release % [‘H]AA release 
36 h in the pre- after 5 h in the after 5 h in the 
sence of 1000 absence of TNF presence of So@0 
U/ml TNF U/ml TNF 
- DEX 25 + 2 2.6 i 0.3 8.3 + 0.7 
+ DEX 16 + 4 2.4 f 0.3 5.3 f 1.0 
a Cell survival in the presence or absence of DEX is shown as cell sur- 
vival % under the same conditions, but in the absence of TNF. Each 
value represents the mean ( f SD) of an experiment carried out in 
triplicate 
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Fig. 1. SDS-PAGE after immunoprecipitation with anti-lipocortin-I 
of [%]methionine-labeled L929 cells treated witb 50rM DEX for the 
times indicated. The position of lipocortin-I is indicated by an arrow. 
and 1000 U TNF/ml were added at different times 
before the end of the labeling (2 h, 4 h, 6 h, 9 h and 21 
h). The lipocortin content of the cells was then deter- 
mined as in section 3.2. A TNF treatment of 21 h 
resulted in considerable cell death. However, the ap- 
parent amounts of lipocortin-I and -11 were not chang- 
, ,,2h,,4h,,6h,,9h,,21h1 E: 
Fig.2. SDS-PAGE after immunoprecipitation with anti-lipocortin-I 
of [35S]methionine-labeled L929 cells treated with 1000 U TNF/ml for 
the times indicated. The position of hpocortin-I is indicated by an 
arrow. 
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Fig.3. SDS-PAGE after immunoprecipitation with anti-lipocortin-I 
and anti-lipocortin-II of [“Slmethionine-labeled TNF-sensitive and 
TNF-resistant L929 cells. 
ed upon TNF-treatment. Data for lipocortin-I are 
shown in fig.2. Similar experiments were performed 
with some other TNF-sensitive cells (HeLaD98/AH2 
and MCF7, which lacked lipocortin-I), leading to the 
same conclusions. In addition, we examined whether 
lipocortin levels differed between TNF-sensitive L929 
cells and their resistant subclones L929rl and L929r2, 
which are fully or partially TNF-resistant, respectively 
(B. Vanhaesebroeck et al., in preparation). However, 
Fig.4. SDS-PAGE after immunoprecipitation with anti-lipocortin-II 
of “Pi-labeled L929 cells treated with 1000 U TNF/ml for the times 
indicated. The position of lipocortin II is indicated by an arrow. 
there was no clear difference in expression of lipo- 
cortin-I or -11 between the different cell types (fig.3). 
3.4. Role of lipocortin phosphorylation in the 
TNF-response 
L929 cell membranes were isolated and treated with 
TNF in the presence of [y-32P]ATP. Lipocortin-I 
phosphorylation was then determined after im- 
munoprecipitation and gel electrophoresis. As a 
positive control we used EGF-induced phosphorylation 
of lipocortin-I in A431 membranes [lo]. We could not 
observe a TNF-induced phosphorylation of lipocortin-I 
in L929 cell membranes (data not shown). Phos- 
phorylation of lipocortin-I and -11 was also studied in 
viable L929 cells which were labeled with “Pi for 3 h 
and treated with TNF for increasing time periods (5 
min, 15 min, 30 min, 1 h, 2 h, 8 h and 18 h) before the 
end of the labeling. In contrast to lipocortin-II, 
lipocortin-I was only very weakly phosphorylated in 
these cells. Again no difference in phosphorylation of 
lipocortins could be seen upon TNF treatment. Data for 
lipocortin-II are shown in fig.4. 
4. DISCUSSION 
In this report we demonstrate that, although both 
TNF-mediated cytotocity and TNF-induced AA release 
are inhibited by DEX, the latter drug has no effect on 
the synthesis of lipocortins. We could also not detect 
constitutive or DEX-induced secretion of lipocortins 
from L929 cells, although there are several reports 
about an extracellular location of these proteins 
[12,13]. Inhibition of cellular PLA2 by extracellular 
lipocortins has been reported by two different groups 
[ 14,151. However, our preliminary results show that ad- 
dition of purified lipocortin-II to L929 cells does not 
block TNF-mediated cytotoxicity or TNF-induced AA 
release. Our results are consistent with a recent report 
which documents the failure to correlate the action of 
lipocortin-I with inhibition by glucocorticoids of 
zymosan-stimulated AA release from macrophages 
[16]. Others also showed that inhibition of thrombox- 
ane A synthesis in U937 cells by glucocorticoids is not 
mediated by lipocortin-I [ 171. The possibility that some 
other recently identified lipocortins [ 181 do play a role 
in TNF action is unlikely as well, since two-dimensional 
gel analysis revealed no induction by DEX of the known 
lipocortins in L929 cell lysates or supernatants, 
although we were able to detect an induction of some 
other proteins by DEX in the same cell lysates (data not 
shown). Experiments to further characterize these pro- 
teins are now in progress. 
The hypothesis that TNF would down-regulate or 
phosphorylate lipocortin-I and -11, in order to activate 
PLA2, is doubtful since we could not detect any effect 
of TNF on the synthesis or phosphorylation of 
lipocortin-I and -11 in L929 cells. Furthermore, there 
95 
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was no difference in the constitutive or TNF-induced 
expression of lipocortin-I and -11 between TNF- 
sensitive and TNF-resistant L929 cells. The activation 
of PLA2 is believed to be responsible for the increase in 
prostaglandin E2 synthesis observed in dermal 
Fibroblasts [19]. However, our preliminary results do 
not show any role of lipocortins in these cells either. 
The rest&s reported above do not support the sugges- 
tion that lipocortins are involved in the reguIation of 
TNF-mediated cytotoxicity. 
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